# Safety and Effectiveness Investigation for Dry, Non-Exudative Age Related Macular Degeneration (AMD) Using Rheopheresis

> **NCT00460967** · PHASE3 · SUSPENDED · sponsor: **OccuLogix** · enrollment: 325 (estimated)

## Conditions studied

- Age-Related Maculopathy

## Interventions

- **DEVICE:** Rheopheresis
- **DEVICE:** Rheopheresis

## Key facts

- **NCT ID:** NCT00460967
- **Lead sponsor:** OccuLogix
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2007-01
- **Primary completion:** —
- **Final completion:** 2009-12
- **Target enrollment:** 325 (ESTIMATED)
- **Why stopped:** In light of the company's current financial position we have indefinately suspended the Rheo-AMD trial.
- **Last updated:** 2007-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00460967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00460967, "Safety and Effectiveness Investigation for Dry, Non-Exudative Age Related Macular Degeneration (AMD) Using Rheopheresis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00460967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*